Pane wikiwiki
ʻO ka pilikia o Nitrosamine i ka hana peptide kahi hopena o kēlā me kēia huahana, ʻaʻole he manaʻo waeʻano. Ma mua o 1,800 Ua hoʻomanaʻo ʻia nā pūʻulu huahana lāʻau i ka…
No ke aha ka pilikia o ka nitrosamine i ka huahana ma mua o ka manaʻo hoʻokahi

Synthesis Of Polypeptide Supplier Pseudoproline Synthesis Pono ʻia kahi loiloi pilikia nitrosamine kikoʻī huahana no ka mea ʻo ka ʻae ʻia e pili ana i ke ʻano o ka nitrosamine., a pili nā laina pilikia i ka synthesis pākahi. ʻO ka wehewehe ʻana a FDA i ke ʻano o ka hoʻokaʻawale ʻana ʻōlelo ʻo ia he ʻokoʻa nā NDSRI i kēlā me kēia lāʻau lapaʻau a ʻaʻohe ʻikepili palekana i loaʻa e hoʻokumu i nā palena AI., no laila e loiloi ʻia kēlā me kēia hale ma o ka pakuhi kahe e hāʻawi ana i kahi ʻāpana potency. ʻO ia ka hapa toxicological o ka hoʻopaʻapaʻa.
ʻO ka hapalua o ke kaʻina hana ʻo ia ka loiloi e ka mea nona ka mana kūʻai aku e hana pū ana me ka API a me nā mea hana huahana i hoʻopau ʻia a me kā lākou mea hoʻolako waiwai., me ka hoʻohana ʻana i nā loina hoʻokele pilikia maikaʻi e like me ka mea i hōʻike ʻia ma ICH Q9, a ʻo ka pilikia i ʻike ʻia ma ka API a i ʻole ka huahana i hoʻopau ʻia e hoʻoulu i ka hoʻāʻo hōʻoia me ka kali ʻole, per ka EMA's nitrosamine Q&A (Rev.23, ʻOkakopa 2025). ʻO ka hopena ʻaʻole hiki ke helu ʻia kahi helu hoʻokahi ma kahi portfolio peptide.

Hoʻokaʻawale nā helu ma muli o ka mana, a ʻo ka ʻokoʻa ka mea nui loa ma ka māhele ikaika loa. ʻO ka papa ʻaina ʻae ʻia e FDA no nā nitrosamines hāʻawi 100 o/lā no ka CPCA Māhele 2, 400 o/lā no Kāwai 3, a 1,500 ng/lā no nā Māhele 4 a 5, oiai ʻO ke alakaʻi o ka nitrosamine Health Canada papa inoa ʻano 1 ma 18 ng/lā a me nā Kāwai 2 ma o 5 ma 100, 400, 1,500 a 1,500 o/lā. Ua ʻae nā papa ʻelua mai Kāwai 2 i luna, no laila, ʻo ke kānāwai kūpono e hōʻailona i ka mana o kēlā me kēia kiʻi ma mua o ka awelika.
ʻO nā mea hoʻokomo peptide-manufacturing hiki ke hoʻokomo i ka pilikia nitrosamine
Palapala ʻāina hiki ke kūkulu ʻia a me nā ala hoʻohaumia: nā amine pilikia a i ʻole nā mea mua, nā mea hana nitrosating, ka hopena a me nā kūlana mālama, mea hana hou, ka hoʻohaumia ʻana a me ka lawe ʻana i nā nitrosamines i hana mua ʻia. ʻO ka loaʻa ʻole o kahi amine i loko o ka huahana i manaʻo ʻia ʻaʻole ia e kāpae i ka haumia nitrosamine.

ʻO ka ʻaoʻao nitrosating o ka pale he papa inoa i wehewehe ʻia. ʻO ke kaʻina hana hoʻokele pilikia o ka lāʻau EFPIA inoa nitrites e like me ka sodium nitrite a me ka waikawa nitrous, nitric oxide, nitrosyl halides, dinitrogen trioxide a me ka dinitrogen tetroxide, a me nā nitrites organik e like me tert-butyl nitrite. Hoʻomaopopo ka kaʻina hana like ʻaʻole ʻo nitrite ponoʻī kahi mea nitrosating akā hiki ke lilo i hoʻokahi ma lalo o nā kūlana e like me ka aqueous acidic media., ʻO kahi ʻokoʻa kūpono ke lawe ʻia i loko o ka moʻolelo no laila ʻaʻole mālama ka mea loiloi i kēlā me kēia ʻōlelo nitrite ma ke ʻano he ʻimi maʻalahi.
ʻO ka papa inoa vulnerable-amine kahi i ʻokoʻa ai nā kaʻina peptide mai nā kaʻina hana liʻiliʻi. ʻO ke kaʻina hana hoʻokele pilikia o ka lāʻau EFPIA nā inoa amine i hoʻokomo ʻia ma ke ʻano he haumia a i ʻole nā mea hoʻohaumia o nā solvents amide DMF, DMAc a me NMP; nā kumu amine tertiary triethylamine, diisopropylethylamine (DIPEA) a me N-methylmorpholine (NMM); nā paʻakai ammonium quaternary e like me ka tetrabutylammonium bromide; a me nā amine mua e like me ka monoethylamine. Hōʻike pū ia i nā mea hoʻokomo paʻa e like me NaCl, NaOH, Hiki iā K2CO3 a me ka lanahu ke lawe i nā pae ppm o nā mea hana nitrosating, oiai ka wai reagents, ʻO nā mea hoʻoheheʻe kūlohelohe a me nā haʻina wai haʻahaʻa pH i manaʻo nui ʻia me ka nitrite-noa.
ʻAʻole hypothetical ka mīkini. He loiloi o nā hanana nitrosamine i kākau ʻia ʻO ka NDMA i loko o ka valsartan i ka dimethylamine ma ke ʻano he mea hoʻohaumia i koe i DMF, ka NMBA precursor i ka degradation o NMP, a me NDIPA a me NEIPA i nā huahana dealkylation o DIPEA. ʻO ka WHO GMP hoʻohui i nā nitrosamines hoʻonohonoho i ka laulā ma ka pae o ke ala o ka synthesis, mea waiwai, nā mea hoʻoheheʻe a me nā mea hana, ʻO ia ka granularity e pono ai ka pale hoʻokomo peptide.
Pehea e hoʻololi ai nā kūlana kaʻina hana i kēlā pilikia
ʻO nā kūlana ʻekolu e hoʻohuli i kahi amine i kēia manawa i loko o kahi nitrosamine i hana ʻia he amine palupalu, he ʻano nitrosating, a me nā kūlana e hui pū ai. ʻO ka Mea Hoʻolako Polypeptide Synthetic Ua ʻōlelo ʻo WHO GMP annex ma nā nitrosamines e hōʻole ʻia ka hoʻohana ʻana i ka nitrite a i ʻole kekahi mea nitrosating agent ma ke ʻano he reagent quenching inā loaʻa nā amine palupalu i kēlā a i ʻole kahi kaʻina hana ma hope a ʻaʻole i hōʻoia ʻia ka pau ʻana., a paipai ʻo ia e hoʻololi i nā nitrites i nā azide decomposition quenches.
ʻO kēlā ʻanuʻu hoʻopau ʻo ia ke ʻano hemahema i kākau ʻia. He loiloi o nā hanana nitrosamine i kākau ʻia wehewehe i ka hoʻopau ʻia ʻana o nā azides i hoʻokō ʻole ʻia mai ka hoʻokumu ʻana o tetrazol ma ka hoʻohui ʻana i ka sodium nitrite i loko o kahi ʻakika., a me nā koena alkyl amine mai nā mea hoʻoheheʻe, ʻO nā reagents a i ʻole ka hoʻohaumia ʻana i luna e hoʻopuka paha i nā nitrosamines pili i ka wā o ia ʻano. Hōʻike ka loiloi like i ka metformin he kūpaʻa paʻa a koi i nā mea hana nitrosating e noho pū ana, ka wai a me ka wela, me nā nitrites a me nā nitrates i loko o nā mea kōkua me ka wai granulation pulu a me ka wela maloʻo e hoʻomaka ana i ka nitrosation.
ʻAʻole pau ka pilikia ma ke ala synthesis. ʻO ka nitrosamine Q o ka EMA&A (Rev.23, ʻOkakopa 2025) ua hoʻohui ʻia ka pilikia o ka hoʻokumu ʻana o ka nitrosamine mai nā mea hana a i ʻole nā mea haumia e pili ana i loko o kahi amine palupalu i ka wā o ka hoʻokumu ʻana a me ka mālama ʻana o ka huahana ma muli o ke ʻano o nā nitrites., a haʻi i nā MAH i noʻonoʻo ʻole i kēia ma ka pae 1 e noʻonoʻo hou i kā lākou loiloi a hoʻomau i ka pae 2 hoʻāʻo e like me ke kūpono. No ka mea hana peptide, ʻo ia hoʻi ka reagent kinai, kona stoichiometry, ʻo ka pH a me ke ʻano o ka hoʻohui ʻia nā mea hoʻololi, a pela no ka maloo ana, ka waiho ʻana a me ka hoʻopaʻa ʻana. ʻO kahi loiloi e kū ana ma ke ala synthesis a ʻaʻole hiki i kēlā mau ʻanuʻu ke waiho ʻole i ke ʻano hemahema, ʻo ia ka wahi e pau ai ka pale ʻana o ka loiloi nitrosamine no ka hana peptide.
Ke hoʻololi nei ke ala synthesis i ka loiloi

ʻAe, hoʻololi ke ala i nā papa reagent e komo i ka loiloi, akā, ʻaʻole ia e hoʻololi i ke ʻano loiloi. ʻO ke kaʻina hana hoʻokele pilikia o ka lāʻau EFPIA hoʻokaʻawale i nā kumu amine a me ka nitrosating-agent e nā reagents, nā catalysts a me nā solvents i hoʻohana ʻia i kahi kaʻina hana, no laila ke ala e hoʻoholo ai i ka papa inoa hoʻokomo ma mua o ka hopena.
Ma SPPS, e loiloi i nā kumu maoli, nā mea hoʻoheheʻe, haumia a me nā kahawai hoʻihoʻi. Piperidine, hoʻohana mau ʻia no ka wehe ʻana iā Fmoc, he amine lua; ʻO DIPEA i hoʻohana ʻia i ka hui ʻana he amine tertiary. ʻOkoʻa ko lākou mau hale a me nā ala ala, no laila, mai wehewehe i nā kumu deprotection a me nā kumu hoʻohui like me nā amine tertiary.
Hoʻoholo pū ka palapala ʻāina i ka mea nona ka moʻolelo. ʻO Bachem's SPPS-specific nitrosamine risk-assessment webinar hoʻonoho i ka CDMO ma ke ʻano he kiaʻi puka no ka hoʻohaumia ʻana o ka nitrosamine ma waena o nā mea hoʻomaka a me ka hoʻokumu ʻana i ka lāʻau, ʻo ia ke kikowaena kahi e hāʻawi maʻemaʻe ai nā palapala a ka mea hoʻolako peptide Hoʻohui Peptoid Māhele Paʻa i ka mea hana huahana i pau. ʻO ke alakaʻi alakaʻi EMA ma nā peptides synthetic hoʻolako i nā palapala i manaʻo ʻia no kahi API peptide synthetic, me nā mea hoʻomaka, reagents a me na haumia, no laila hiki ke kūkulu ʻia ka faila nitrosamine ma ke ʻano he hoʻonui o ka faila CMC ma mua o ka hoʻoikaika like.
He aha nā mana analytical a me ka hōʻoia hōʻoia e pono ai ka loiloi
Ua lawa ke ala hōʻoia i ka wā e noho ana kona palena helu ma lalo a i ʻole ka pae āu e hoʻomalu ai, a i ka wā e uhi ai kāna pūʻolo hōʻoia i ka matrix āu e holo maoli ai. I Q2(R2) koi ʻia no nā hoʻāʻo haumia ʻo QL no ke kaʻina hana analytical e like a ma lalo paha o ka paepae hōʻike., a pono ia mea kiko'ī, laula, pololei, ka hana hou a me ka pololei waena no ka ho'āʻo haumia quantitative. ʻO ke alakaʻi like ka wehewehe ʻana i ka palena quantitation e like me ka haʻahaʻa haʻahaʻa o ka analyte i loko o kahi laʻana i hiki ke hoʻoholo ʻia me ka pololei a me ka pololei..
<papa helu ="blog-chart" kaila="laula-nui:640px;palena palena:1.5rem auto;nui-momona:12px;kiʻekiʻe laina:1.3;kala kala:hooilina"> <svg viewBox="0 0 560 380" kaila="laula-nui: 100%; kiekie: kaʻa; font-ohana: 'Inter', ʻōnaehana-ui, sans-serif; kala kala: #1e293b; --pakuhi-muted: #64748b;" kuleana="img" aria-labelledby="nitrosamine-metod-sensitivity-vs-required-limits-title nitrosamine-method-sensitivity-vs-required-limits-desc"> <kaila> /* Hoʻokomo ka mea hāʻawi i ka pakuhi i loko o kahi iframe nona ka ʻeleʻele ʻeleʻele, a he ʻano ʻokoʻa ka iframe i ka pakuhi, no laila ua hōʻike ʻia nā pahu pahu leka me he mau papa ʻeleʻele a puni (prod 09-22). Akaka ka palapala i loko o ka iframe ma ka paʻamau; ʻO ka pena kiʻi ma ʻaneʻi e uhi ana i ke kāʻei o ka element, a ke kau ʻia ka pakuhi, ʻaʻohe mea pili kēia. E mālama i nā pale kihi ma waho o kēia poloka: ʻO kahi mea ʻano i loko o kahi SVG i hoʻokaʻawale ʻia ma ke ʻano he ʻike haole, no laila, hoʻolei kekahi bracket hele i kēlā me kēia lula i loko. */ html, kino { hope: #ffffff; palena palena: 0; } @media (makemake-hoemi-holo: hoemi) { * { hoʻouluulu: ʻaʻohe !mea nui; hoʻololi: ʻaʻohe !mea nui; } } </kaila> <pololei x="0" y="0" laula="560" kiekie="380" rx="8" hoʻopiha="#ffffff" /> <inoa id="nitrosamine-method-sensitivity-vs-required-limits-title">ʻO ke ʻano o ke ala Nitrosamine me nā palena i koi ʻia</inoa> <wehewehe id="nitrosamine-metod-sensitivity-vs-required-limits-desc">ʻO ke ʻano o ke ala Nitrosamine me nā palena i koi ʻia: nā waiwai no GC-MS/MS, LC-MS/MS (haʻahaʻa), LC-MS/MS (kiʻekiʻe), FDA LC-HRMS, ʻO Sitagliptin NDSRI. ʻO ke ʻano o ke ala Nitrosamine me nā palena i koi ʻia. ʻikepili pae pae: GC-MS/MS 0.005; LC-MS/MS (haʻahaʻa) 0.01; LC-MS/MS (kiʻekiʻe) 0.02; FDA LC-HRMS 0.05; ʻO Sitagliptin NDSRI 0.1; palena ma 300 mg / lā 0.088. Puna: EMA Q&A, EMA/409815/2020 Rev.23 2025-10-10.</wehewehe> <kikokikona x="280.0" y="29" heleuma kikokikona="waena" font-size="18" font-kaumaha="800" hoʻopiha="kala kala">ʻO ke ʻano o ke ala Nitrosamine me nā palena i koi ʻia</kikokikona> <laina x1="145" y1="298.0" x2="510" y2="298.0" hahau ="kala kala" opacity="0.08" /> <laina x1="145" y1="243.0" x2="510" y2="243.0" hahau ="kala kala" opacity="0.08" /> <laina x1="145" y1="188.0" x2="510" y2="188.0" hahau ="kala kala" opacity="0.08" /> <laina x1="145" y1="133.0" x2="510" y2="133.0" hahau ="kala kala" opacity="0.08" /> <laina x1="145" y1="78.0" x2="510" y2="78.0" hahau ="kala kala" opacity="0.08" /> <kikokikona x="136.0" y="97.5" heleuma kikokikona="hopena" font-size="11" hoʻopiha="kala kala" opacity="0.8"><puna x="136.0" dy="0">GC-MS/MS</tspan></kikokikona> <pololei x="145" y="78.0" laula="1.8" kiekie="30.0" rx="4" hoʻopiha="#f97316" /> <kikokikona x="154.8" y="97.5" font-size="11" hoʻopiha="kala kala">0.005</kikokikona> <kikokikona x="136.0" y="135.5" heleuma kikokikona="hopena" font-size="11" hoʻopiha="kala kala" opacity="0.8"><puna x="136.0" dy="0">LC-MS/MS (haʻahaʻa)</tspan></kikokikona> <pololei x="145" y="116.0" laula="3.6" kiekie="30.0" rx="4" hoʻopiha="#38bdf8" /> <kikokikona x="156.7" y="135.5" font-size="11" hoʻopiha="kala kala">0.01</kikokikona> <kikokikona x="136.0" y="173.5" heleuma kikokikona="hopena" font-size="11" hoʻopiha="kala kala" opacity="0.8"><puna x="136.0" dy="0">LC-MS/MS (kiʻekiʻe)</tspan></kikokikona> <pololei x="145" y="154.0" laula="7.3" kiekie="30.0" rx="4" hoʻopiha="#a78bfa" /> <kikokikona x="160.3" y="173.5" font-size="11" hoʻopiha="kala kala">0.02</kikokikona> <kikokikona x="136.0" y="211.5" heleuma kikokikona="hopena" font-size="11" hoʻopiha="kala kala" opacity="0.8"><puna x="136.0" dy="0">FDA LC-HRMS</tspan></kikokikona> <pololei x="145" y="192.0" laula="18.2" kiekie="30.0" rx="4" hoʻopiha="#22c55e" /> <kikokikona x="171.2" y="211.5" font-size="11" hoʻopiha="kala kala">0.05</kikokikona> <kikokikona x="136.0" y="249.5" heleuma kikokikona="hopena" font-size="11" hoʻopiha="kala kala" opacity="0.8"><puna x="136.0" dy="0">ʻO Sitagliptin</tspan><puna x="136.0" dy="12">NDSRI</tspan></kikokikona> <pololei x="145" y="230.0" laula="36.5" kiekie="30.0" rx="4" hoʻopiha="#maka15" /> <kikokikona x="189.5" y="249.5" font-size="11" hoʻopiha="kala kala">0.1</kikokikona> <kikokikona x="136.0" y="287.5" heleuma kikokikona="hopena" font-size="11" hoʻopiha="kala kala" opacity="0.8"><puna x="136.0" dy="0">Ka palena ma 300</tspan><puna x="136.0" dy="12">mg / lā</tspan></kikokikona> <pololei x="145" y="268.0" laula="32.1" kiekie="30.0" rx="4" hoʻopiha="#fb7185" /> <kikokikona x="185.1" y="287.5" font-size="11" hoʻopiha="kala kala">0.088</kikokikona> <kikokikona x="280.0" y="366" heleuma kikokikona="waena" font-size="10" hoʻopiha="kā mākou(--pakuhi-muted, kala kala)">Puna: EMA Q&A, EMA/409815/2020 Rev.23 (2025-10-10)</kikokikona> </svg> </huahelu>
Me AI i ng / lā a me ka nui loa o kēlā me kēia lā M i mg / lā, Hāʻawi ʻo AI / M i ka ʻike ma ng / mg, helu like me ka ppm. Hōʻike ʻia ma ppb, e hoonui i kela waiwai me 1,000. E hoʻohana a hoʻohana i nā lula pili aupuni no nā nitrosamines lehulehu, haʻalele a hōʻemi ʻia ka hoʻāʻo ʻana.
Hāʻawi ka hoʻokō ʻana i ke ʻano i paʻi ʻia iā ʻoe i ke ʻano hōʻailona. A 2025 hōʻuluʻulu manaʻo o ka nitrosamine analytical kaʻina hana loiloi LC-MS/MS ma 0.05 ppm, ʻO nā ala GC-MS/MS e like me ka haʻahaʻa 0.001 ppm, a me kahi ala FDA LC-HRMS ma 1 o/mL, me NDMA a me NDEA a puni 0.1 i 0.5 ng/mL ma kahi 5 kumu hoʻohālike mg/mL. Loaʻa kēlā mau kiʻi mai nā API mole liʻiliʻi a me nā matrices sartan, no laila he mau hōʻailona, ʻaʻole hana peptide: peptide-matrix LOQ pili i nā hopena matrix, laʻana hoʻomākaukau a me ka polarity o ka pahu hopu, a ʻaʻohe LOQ nitrosamine i paʻi ʻia i ana ʻia i loko o kahi peptide drug-substance matrix i loaʻa no kēia ʻatikala. E hōʻike i ka matrix me kēlā me kēia LOQ āu e haʻi ai.
Ho'āʻo cadence ma hope o ka hopena pilikia. ʻO ka nitrosamine Q o ka EMA&A (Rev.23, ʻOkakopa 2025) kau i ka hoao ana ma 10% o na hui makahiki a i ole 3 i kēlā me kēia makahiki, o ka mea kiekie, kahi i hoʻomaopopo ʻia ai ke kumu o ka pōʻino a ʻo nā pae e kū like ana i kēlā me kēia pūʻulu, a koi ʻia nā pūʻulu a pau e hoʻāʻo ʻia ma kahi i hana ʻia ma lalo o ʻekolu i kēlā me kēia makahiki. ʻO ka papa inoa o ka nitrosamine maʻamau ka papa inoa o ka MHRA nā inoa kūpono ʻole o nā ʻano analytical a me ka loiloi pilikia ʻole i waena o nā hemahema i hōʻole ʻia., ʻO ia ke kumu e lawe ai ka papa helu loiloi loiloi pilikia nitrosamine i ka LOQ o ke ʻano, kona matrix a me kona kūlana hōʻoia ma ke ʻano he laina laina ʻokoʻa.
He aha nā moʻolelo e hiki ai ke hoʻopaʻa ʻia ka hopena no ka loiloi mea kūʻai aku a mea hoʻoponopono paha
ʻO ka pūʻulu moʻolelo e ola ana i ka loiloi ʻana ʻo ia ka mea e hoʻohālike i nā kahua hoʻohālike kūhelu, no ka mea, ʻo ia ka mea e hoʻohālikelike ai ka mea loiloi. ʻO ka CMDh nitrosamine ka loiloi loiloi pilikia pono i ka inoa MAH a me ka helu wahi; ke ʻano huahana; ka huahana a me ka API a i ʻole ka inoa waena; ka helu mana kuai; ka helu kaʻina hana EU no nā huahana MRP a i ʻole DCP; ka inoa a me ka helu wahi o ka mea hana API; ka inoa a me ka helu wahi o ka mea hana huahana; ka manawa hōʻoia hōʻoia; me ka hoʻokaʻawale ʻana o ka pilikia kiʻekiʻe, haʻahaʻa a haʻahaʻa a he kumu kumu e uhi ana i ka hana ʻana a i ʻole ka hoʻohaumia kea, hoʻohua a kūpaʻa paha, hua hoʻohuihui, a me ka hana in-vivo. Pono ka faila a ka mea hoʻolako peptide e hoʻopiha i kēlā me kēia kahua no ka ʻāpana API.
ʻO nā kuʻina palapala e hiki ai ke pale aku i kēlā mau māla, ʻo ia nā mea e pili ana i kekahi moʻolelo pūʻulu. Pono e nānā ʻia kahi palapala hōʻoia no ka hoʻopaʻa ʻana ma ke ʻano he moʻolelo kikoʻī pūʻulu ma mua o kahi ʻōlelo kūʻai maʻamau, a ʻaʻole i hoʻokumu ʻia kahi pākēneka maʻemaʻe wale nō: ka maemae, ʻike ʻike, ʻano hana, pono e loiloi pū ʻia ka helu hailona a me nā palapala. ʻO ka WHO GMP hoʻohui i nā nitrosamines hoʻohui i nā moʻolelo kaulahao hoʻolako i manaʻo ʻia e mālama ʻia, me ka inoa o ka mea hana maka-mea a me ka mea hoolako, nā kuleana o nā mea hana maoli, a me nā mea hoʻopili hou a me nā mea hoʻolaha e mālama i nā mea ma mua o ka hana ʻana o API.
ʻAʻole pani ka pepa mea kūʻai aku i ka nīnau nona iho. ʻO ke alakaʻi o ka nitrosamine Health Canada states that manufacturer and supplier declarations are not a substitute for an overall robust risk assessment by the MAH, a ka EMA's nitrosamine Q&A (Rev.23, ʻOkakopa 2025) places the duty on the MAH to work with API suppliers to ensure acceptable API quality, including tighter amine limits than the pharmacopoeial monograph where the finished product needs them. A supplier declaration is an input to the file, not the conclusion of it.
ʻO ka manawa hea e koi ʻia ai ka hoʻāʻo hōʻoia me ka wā e pani ʻia ai kahi loiloi maikaʻi ʻole i kākau ʻia i ka nīnau

<papa helu ="blog-chart" kaila="laula-nui:640px;palena palena:1.5rem auto;nui-momona:12px;kiʻekiʻe laina:1.3;kala kala:hooilina"> <svg viewBox="0 0 560 380" kaila="laula-nui: 100%; kiekie: kaʻa; font-ohana: 'Inter', ʻōnaehana-ui, sans-serif; kala kala: #1e293b; --pakuhi-muted: #64748b;" kuleana="img" aria-labelledby="confirmatory-testing-burden-when-risk-is-identified-title confirmatory-testing-burden-when-risk-is-identified-desc"> <kaila> /* Hoʻokomo ka mea hāʻawi i ka pakuhi i loko o kahi iframe nona ka ʻeleʻele ʻeleʻele, a he ʻano ʻokoʻa ka iframe i ka pakuhi, no laila ua hōʻike ʻia nā pahu pahu leka me he mau papa ʻeleʻele a puni (prod 09-22). Akaka ka palapala i loko o ka iframe ma ka paʻamau; ʻO ka pena kiʻi ma ʻaneʻi e uhi ana i ke kāʻei o ka element, a ke kau ʻia ka pakuhi, ʻaʻohe mea pili kēia. E mālama i nā pale kihi ma waho o kēia poloka: ʻO kahi mea ʻano i loko o kahi SVG i hoʻokaʻawale ʻia ma ke ʻano he ʻike haole, no laila, hoʻolei kekahi bracket hele i kēlā me kēia lula i loko. */ html, kino { hope: #ffffff; palena palena: 0; } @media (makemake-hoemi-holo: hoemi) { * { hoʻouluulu: ʻaʻohe !mea nui; hoʻololi: ʻaʻohe !mea nui; } } </kaila> <pololei x="0" y="0" laula="560" kiekie="380" rx="8" hoʻopiha="#ffffff" /> <inoa id="confirmatory-testing-burden-when-risk-is-identified-title">Confirmatory testing burden when risk is identified</inoa> <wehewehe id="confirmatory-testing-burden-when-risk-is-identified-desc">Where risk is identified, EMA expects testing on 10% o na hui makahiki a i ole 3 i kēlā me kēia makahiki, o ka mea kiekie, a me nā pūʻulu a pau ke emi iho 3 hana ʻia i kēlā me kēia makahiki. Confirmatory testing burden when risk is identified. ʻikepili lollipop: He emi mai 3 pūʻulu / makahiki 3; 10% o na puu makahiki 10; ʻO ka liʻiliʻi i kēlā me kēia makahiki 3.Source: EMA Q&A, EMA/409815/2020 Rev.23, Q&A 8 2025-10-10.</wehewehe> <kikokikona x="280.0" y="29" heleuma kikokikona="waena" font-size="18" font-kaumaha="800" hoʻopiha="kala kala">Confirmatory testing burden when risk is identified</kikokikona> <laina x1="145" y1="298.0" x2="510" y2="298.0" hahau ="kala kala" opacity="0.08" /> <laina x1="145" y1="243.0" x2="510" y2="243.0" hahau ="kala kala" opacity="0.08" /> <laina x1="145" y1="188.0" x2="510" y2="188.0" hahau ="kala kala" opacity="0.08" /> <laina x1="145" y1="133.0" x2="510" y2="133.0" hahau ="kala kala" opacity="0.08" /> <laina x1="145" y1="78.0" x2="510" y2="78.0" hahau ="kala kala" opacity="0.08" /> <kikokikona x="136.0" y="118.7" heleuma kikokikona="hopena" font-size="11" hoʻopiha="kala kala" opacity="0.8"><puna x="136.0" dy="0">ʻOi aʻe ma mua o 3</tspan><puna x="136.0" dy="12">pūʻulu / makahiki</tspan></kikokikona> <laina x1="145" y1="114.7" x2="254.5" y2="114.7" hahau ="kala kala" opacity="0.15" kaha-ākea="1" /> <pōʻai cx="254.5" cy="114.7" r="6" hoʻopiha="#f97316" /> <kikokikona x="266.5" y="118.7" font-size="11" hoʻopiha="kala kala">3</kikokikona> <kikokikona x="136.0" y="192.0" heleuma kikokikona="hopena" font-size="11" hoʻopiha="kala kala" opacity="0.8"><puna x="136.0" dy="0">10% o ka makahiki</tspan><puna x="136.0" dy="12">pūʻulu</tspan></kikokikona> <laina x1="145" y1="188.0" x2="510.0" y2="188.0" hahau ="kala kala" opacity="0.15" kaha-ākea="1" /> <pōʻai cx="510.0" cy="188.0" r="6" hoʻopiha="#38bdf8" /> <kikokikona x="522.0" y="192.0" font-size="11" hoʻopiha="kala kala">10</kikokikona> <kikokikona x="136.0" y="265.3" heleuma kikokikona="hopena" font-size="11" hoʻopiha="kala kala" opacity="0.8"><puna x="136.0" dy="0">Ka palena iki o ka makahiki</tspan></kikokikona> <laina x1="145" y1="261.3" x2="254.5" y2="261.3" hahau ="kala kala" opacity="0.15" kaha-ākea="1" /> <pōʻai cx="254.5" cy="261.3" r="6" hoʻopiha="#a78bfa" /> <kikokikona x="266.5" y="265.3" font-size="11" hoʻopiha="kala kala">3</kikokikona> <kikokikona x="280.0" y="366" heleuma kikokikona="waena" font-size="10" hoʻopiha="kā mākou(--pakuhi-muted, kala kala)">Puna: EMA Q&A, EMA/409815/2020 Rev.23, Q&A 8 (2025-10-10)</kikokikona> </svg> </huahelu>
Pono ka hoʻāʻo hōʻoia inā ʻike ka loiloi pilikia i kahi pilikia, a ʻaʻole i manaʻo ʻia ke hoʻopau ka loiloi ʻaʻole ʻike ʻia kahi pilikia. ʻO ke alakaʻi o ka nitrosamine Health Canada ʻōlelo ʻo ia ʻaʻole i manaʻo ʻia ka hoʻāʻo hōʻoia inā pau ka loiloi pilikia ʻaʻole ʻike ʻia ka pilikia, a ka EMA's nitrosamine Q&A (Rev.23, ʻOkakopa 2025) hoʻonoho i ke kumu ma kekahi ʻaoʻao: inā ʻike ʻia kahi pilikia ma ka API a i ʻole ka huahana i hoʻopau ʻia, pono e hoʻolaha ka MAH i nā mana kūpono a hoʻomau me ka hoʻokaʻulua ʻole me nā hoʻokolohua hōʻoia.
Hiki ke kūpono i kahi hopena pili ʻole i kākau ʻia ke kākoʻo ʻia ka loiloi huahana a me ke kaʻina hana. Hoʻopaʻa i nā manaʻo, hōʻike hoʻolako, nā mana hoʻohaumia, hoʻokumu a hoʻomaʻemaʻe i ka noʻonoʻo, a me nā hoʻololi e wehe hou i ka loiloi; ʻaʻole lawa ka pale amine maikaʻi wale nō. Spot Peptide Synthesis
ʻO nā hoʻoholo hoʻoholo hōʻoia a hōʻemi ʻia e pili ana i ke alakaʻi kūpono, ana pae, ka hoʻomaopopo ʻana a me ke kūpaʻa. Mai mālama i kahi hakina AI haʻahaʻa a i ʻole kahi mea mua i ʻike ʻole ʻia ma ke ʻano he ʻae kumu ʻole e haʻalele i nā mana.. E hoʻopaʻa i ka mana alakaʻi a me nā hōʻike e ʻoluʻolu i kēlā me kēia kūlana.
Nīnau pinepine
Pono kēlā me kēia peptide i ka hoʻāʻo nitrosamine hōʻoia?
E hahai ana ka ho'āʻo ʻana i ka loiloi pilikia kikoʻī o ka huahana a me nā manaʻolana hoʻoponopono kūpono. ʻAʻole i hōʻoia ka loaʻa ʻana o kahi amine wale nō i ka hoʻokumu ʻana o ka nitrosamine a i ʻole hoʻoholo ʻokoʻa i ka hoʻāʻo. E noʻonoʻo i ka maʻalahi o ka amine, nā kumu nitrosating, kaʻina hana, haumia, ka hana ʻana a me ka mālama ʻana; e nānā i ka hopena ke loli ka ʻike pili. Mea kūʻai kūʻai nui Peptide
ʻO ka palena ʻae ʻae ʻia e haʻi ʻia e kahi mea hana peptide?
ʻO ka mea i mana ma ka mana i kākau ʻia ai ka faila, inoa me ka helu. ʻAʻole kūlike nā palena ma ka palena haʻahaʻa. ʻO ka papa CPCA o Health Canada sets Kāwai 1 ma 18 o/lā, oiai ʻO ka papa ʻaina ʻae ʻia e FDA no nā nitrosamines pili 26.5 ng/lā i ka māhele like. Māhele 2 ma o 5 aelike ma 100, 400, 1,500 a 1,500 o/lā. ʻAwelika ʻelua Māhele 1 hewa nā waiwai; E koho i ke aupuni e hoʻokele i ka huahana a ʻōlelo i loko o ka faila. Ma kahi o ʻelua nitrosamine, Hoʻopili ke kānāwai kumulative-limit o Health Canada i ka NDMA me NMBA ma 96.0 o/lā a me NDMA me NDEA a me 26.5 o/lā, no laila, ʻaʻole ʻo ka helu haumia hoʻokahi ka helu holoʻokoʻa.
Pehea ka maʻalahi o ke ʻano o ka nitrosamine?
Hiki ke hōʻike i ka pae ma lalo o ka paepae e hilinaʻi ai ka loiloi, ʻo ia ka hapa o ka palena kikoʻī huahana ma mua o ka palena ponoʻī. I Q2(R2) koi i ka palena nui o ke kaʻina hana haumia ma lalo a i ʻole ka paepae hōʻike, a wehewehe i kēlā palena ʻo ia ka huina haʻahaʻa i hiki ke hoʻoholo me ka pololei a me ka pololei. ʻO nā ʻano nitrosamine i paʻi ʻia e hōʻea i nā palena helu ma nā ʻāpana haʻahaʻa-per-biliona, akā, hele mai kēlā mau huahelu mai nā matrices liʻiliʻi. ʻAʻohe kiʻi peptide-matrix i loaʻa, no laila pono e hōʻike ʻia ka naʻau ma ka matrix ponoʻī o ka mea hana ma mua o ka ʻaiʻē ʻana mai ka palapala.
Ua lawa ka ʻōlelo hoʻolako e pani i kahi laina pilikia?
ʻAʻole. ʻO ka haʻi ʻōlelo he mea hoʻokomo i ka loiloi, aole he pani no ia mea. ʻO ke alakaʻi o ka nitrosamine Health Canada ʻōlelo ʻo ia ʻaʻole e pani nā ʻōlelo a ka mea hana a me nā mea hoʻolako i ka loiloi koʻikoʻi koʻikoʻi o ka mea hana, a ka WHO GMP annex ma nitrosamines pono e nānā ʻia nā kaulahao hoʻolako no nā mea pilikia. ʻAʻole hiki ke heluhelu ʻia ka ʻikepili nitrite mea hoʻolako ma ke ʻano he palena maʻamau: ʻO ka hoʻolaha hoʻolaha hoʻokele pilikia o ka nitrosamine huahana kikoʻī a Capsugel e pili ana i ka unuhi ʻana i kahi ʻae ʻae ʻia i loko o kahi palena koʻikoʻi kikoʻī o ka huahana ma muli o ka haku mele., no laila, ʻo ke kiʻi nitrite hoʻokahi ke ʻano o nā mea like ʻole i nā ʻano hana like ʻole.
I ka manawa hea e pau ai ka ICH M7 nitrosamine addendum?
ʻAʻole i hoʻopaʻa ʻia kahi pahuhopu hoʻolālā hana. E nānā i ke kūlana mālama ICH M7 o kēia manawa a me ke alakaʻi nitrosamine kūloko i ka wā e hoʻolālā ai i ka loiloi.
Ka hopena
E hoʻomaka mai ka huahana a me ke ala, a laila kūkulu palapala ʻāina, haumia, nā ala lawe a mālama. E loiloi i nā mana a me nā hōʻike analytical pono e kākoʻo i kēlā me kēia hopena, e palapala i ke koena o ka maopopo ole a hoonoho i na kumu hooponopono.
ʻO ka hoʻonohonoho moʻolelo ka mea e ola ai ka hopena o ka loiloi. ʻO ka CMDh nitrosamine ka loiloi loiloi pilikia wehewehe i na kahua, a ʻO ke alakaʻi o ka nitrosamine Health Canada wehewehe i ka palena o ka mea e hiki ke lawe i nā pepa mea hoʻolako. E kūkulu i ka papa inoa loiloi loiloi pilikia nitrosamine a puni ia mau kahua, e mālama i ka LOQ a me ka matrix i hoʻopili ʻia i ka laina pilikia e pani ai, a lepili i ka mana ma kēlā me kēia kiʻi i ʻae ʻia.
Pono nā palena ʻelua e haʻi maʻalahi. Hoʻopaʻa kēia anga i kahi hopena pilikia no nā peptides synthesized kemika; ʻaʻole ia e pani i kahi loiloi toxicological kikoʻī huahana. A ʻaʻole i paʻi ʻia ka nitrosamine LOQ i ana ʻia i loko o kahi peptide drug-substance matrix i loaʻa no kēia ʻatikala, no laila, pono e ho'okumu 'ia ka 'ano na'au i loko o kāu matrix ma mua o ka lawe 'ia 'ana mai kahi paena li'ili'i. Kaʻina aʻe: palapala i kāu kōpili peptide i kēia manawa e pili ana i ka pale hoʻokomo a ʻike i nā huahana he amine a me kahi hoa nitrosating ma ke kahawai kaʻina like..
